ClinicalTrials.gg
CompletedNCT00827606Updated Feb 21, 2021Results posted

Atorvastatin Three Year Pediatric Study

A Phase 3 interventional study of atorvastatin in Familial Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 40 sites in 15 countries. Open to participants aged 6 Years to 15 Years. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
272
Allocation
Not applicable
Ages
6 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Hyperlipoproteinemia Type II with a site in United States — 17 open to participants now, 18 under way, 6 of them phase 3. Hyperlipoproteinemia Type II · United States.

Enrollment
27th of 68
272 · median 163
Started
2009
with 2 others
Phase 3
30 of 76
5 open now
Registered
18th of 76
by date

Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, this one is the 27th largest by enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2009, is one of 30 in phase 3, and was the 18th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

17 of the 76 studies in Hyperlipoproteinemia Type II with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 6 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Hyperlipoproteinemia Type II with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to characterize three year descriptive growth and development (ie, height, weight, body mass index, Tanner Stage) and efficacy of cholesterol reduction in pediatric subjects with Heterozygous Familial Hypercholesterolemia receiving atorvastatin treatment.

03

Conditions studied

  • Familial Hypercholesterolemia

Keywords

  • pediatric heterozygous familial hypercholesterolemia
04

Who can participate

Ages eligible
6 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Heterozygous familial hypercholesterolemia, ages 6-15, LDL greater than 4 mmol/l

Exclusion criteria

Exclusion Criteria:

  • Active liver disease or hepatic dysfunction, or persistent elevations of serum transaminases exceeding three times the (ULN).

Female of who is not using adequate measures or any female who is pregnant or breastfeeding. Any female who becomes pregnant during study participation will be immediately discontinued from treatment and counseled appropriately about the in utero exposure.

Known to HMG-CoA reductase inhibitors

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
272 participants (actual)

Study arms

  • Experimental
    Atorvastatin

    All subjects will be treated with atorvastatin

    Drug: atorvastatin

Interventions

  • Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)

06

What researchers measure

Primary outcomes

  1. Low Density Lipoprotein Cholesterol (LDL-C; Millimoles Per Liter [mMol/L]) During the Study

    Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36 (or early termination [ET])

  2. Percent Change From Baseline in LDL-C

    Assessments were performed in the fasting state (minimum 10-hour fast).

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36 (or ET)

  3. High-Density Lipoprotein Cholesterol (HDL-C; mMol/L) During the Study

    Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  4. Percent Change From Baseline in HDL-C

    Assessments were performed in the fasting state (minimum 10-hour fast).

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  5. Total Cholesterol (mMol/L) During the Study

    Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  6. Percent Change From Baseline in Total Cholesterol

    Assessments were performed in the fasting state (minimum 10-hour fast).

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  7. Trigylcerides (mMol/L) During the Study

    Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  8. Percent Change From Baseline in Trigylcerides

    Assessments were performed in the fasting state (minimum 10-hour fast).

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  9. Very Low-Density Lipoprotein (VLDL; mMol/L) During the Study

    Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  10. Percent Change From Baseline in VLDL

    Assessments were performed in the fasting state (minimum 10-hour fast).

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  11. Apoliprotein A-1 (Apo A-1; Grams Per Liter [g/L]) During the Study

    Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  12. Percent Change From Baseline in Apo A-1

    Assessments were performed in the fasting state (minimum 10-hour fast).

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  13. Apoliprotein B (Apo B; g/L) During the Study

    Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  14. Percent Change From Baseline in Apo B

    Assessments were performed in the fasting state (minimum 10-hour fast).

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  15. Number of Participants With Shift From Baseline in Tanner_Stage by Timepoint and Baseline Tanner_Stage

    Tanner_Stage was assessed based on 2 components by gender, pubic hair and breasts for females and pubic hair and genitalia for males. If these values of components were not same, then the Tanner_Stage had the higher value of 2 components for each gender by visit.

    Time frame: Baseline, Months 6, 12, 18, 24, 30, and 36/ET

  16. Height (Centimeters [cm]) During the Study: Males

    Investigator assessment of height changes during the study. Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  17. Percent Change From Baseline in Height: Males

    Investigator assessment of height changes during the study.

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  18. Height (cm) During the Study: Females

    Investigator assessment of height changes during the study. Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  19. Percent Change From Baseline in Height: Females

    Investigator assessment of height changes during the study.

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  20. Weight (Kilograms [kg]) During the Study: Males

    Investigator assessment of weight changes during the study. Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  21. Percent Change From Baseline in Weight: Males

    Investigator assessment of weight changes during the study.

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  22. Weight (kg) During the Study: Females

    Investigator assessment of weight changes during the study. Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  23. Percent Change From Baseline in Weight: Females

    Investigator assessment of weight changes during the study.

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  24. Body Mass Index (BMI in kg Per Square Meter [kg/m^2]) During the Study: Males

    Investigator assessment of BMI changes during the study. Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  25. Percent Change From Baseline in BMI: Males

    Investigator assessment of BMI changes during the study.

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  26. BMI (kg/m^2) During the Study: Females

    Investigator assessment of BMI changes during the study. Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  27. Percent Change From Baseline in BMI: Females

    Investigator assessment of BMI changes during the study.

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  28. Age (Years) During the Study: Males

    Investigator assessment of age during the study. Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  29. Percent Change From Baseline in Age: Males

    Investigator assessment of age during the study.

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  30. Age (Years) During the Study: Females

    Investigator assessment of age during the study. Change from baseline was also determined.

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  31. Percent Change From Baseline in Age: Females

    Investigator assessment of age during the study.

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET

  32. Flow-Mediated Dilatation (FMD) During the Study

    Percent (%) FMD was calculated as (hyperemic diameter minus resting diameter) divided by the resting diameter multiplied by 100. Change from baseline was also determined.

    Time frame: Baseline, Months 6, 12, 18, 24, 30 and 36/ET

  33. Percent Change From Baseline in FMD

    Percent (%) FMD was calculated as (hyperemic diameter minus resting diameter) divided by the resting diameter multiplied by 100.

    Time frame: Months 6, 12, 18, 24, 30 and 36/ET

Secondary outcomes

  1. Percentage of Participants With Overall Expected Maturation and Development Consistent With Expectations as Assessed by the Investigator

    Time frame: Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36 (or early termination)

  2. Percentage of Participants by Study Drug Compliance Category

    Compliance to study drug was categorized as \<80%, 80% - 120%, and greater than (\>) 120%.

    Time frame: Months 1, 2, 3, 6, 12, 18, 24, 30, and 36 (or early termination)

07

Results

Posted Jun 2, 2015

Participant flow

Participant flow — Overall Study
MilestoneAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Started139132
Completed11294
Not completed2738
Withdrew: Protocol violation43
Withdrew: Lost to follow-up31
Withdrew: Withdrawal by subject76
Withdrew: Pregnancy01
Withdrew: Other513
Withdrew: Ldl below 2.59 mmol/l412
Withdrew: Adverse event42

Outcome measures

PrimaryLow Density Lipoprotein Cholesterol (LDL-C; Millimoles Per Liter [mMol/L]) During the Study

Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36 (or early termination [ET])
Reported as:
Mean · mMol/L
Low Density Lipoprotein Cholesterol (LDL-C; Millimoles Per Liter [mMol/L]) During the Study
mMol/LAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Baseline (n=139,132)6.304 ± 1.31305.921 ± 1.1646
Month 1 (n=131,130)4.087 ± 1.02643.675 ± 0.8749
Change at Month 1 (n=131,130)-2.214 ± 0.7568-2.233 ± 0.8009
Month 2 (n=132,122)3.719 ± 0.83463.437 ± 0.7438
Change at Month 2 (n=132,122)-2.586 ± 0.9297-2.554 ± 0.9155
Month 3 (n=126,117)3.503 ± 0.75663.270 ± 0.6533
Change at Month 3 (n=126,117)-2.798 ± 1.0251-2.795 ± 1.0835
Month 6 (n=127,115)3.366 ± 0.57873.347 ± 0.5953
Change at Month 6 (n=127,115)-2.968 ± 1.1096-2.732 ± 1.0660
Month 12 (n=121,109)3.409 ± 0.73953.196 ± 0.6565
Change at Month 12 (n=121,109)-2.966 ± 1.0987-2.838 ± 1.1450
Month 18 (n=116,101)3.309 ± 0.59333.261 ± 0.5288
Change at Month 18 (n=116,101)-3.105 ± 1.1558-2.835 ± 1.2128
Month 24 (n=111,96)3.316 ± 0.68033.189 ± 0.6537
Change at Month 24 (n=111,96)-3.088 ± 1.2026-2.933 ± 1.2292
Month 30 (n=112,94)3.335 ± 0.64903.142 ± 0.6916
Change at Month 30 (n=112,94)-3.090 ± 1.2402-3.008 ± 1.1489
Month 36/ET (n=123,117)3.450 ± 0.73723.457 ± 0.8808
Change at Month 36/ET (n=123,117)-2.855 ± 1.2625-2.468 ± 1.3270
PrimaryPercent Change From Baseline in LDL-C

Assessments were performed in the fasting state (minimum 10-hour fast).

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36 (or ET)
Reported as:
Mean · percent change
Percent Change From Baseline in LDL-C
percent changeAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Month 1 (n=131,130)-34.995 ± 9.7300-37.516 ± 10.0245
Month 2 (n=132,122)-40.371 ± 9.6468-41.939 ± 10.4816
Month 3 (n=126,117)-43.568 ± 10.2149-44.887 ± 12.7530
Month 6 (n=127,115)-45.647 ± 9.6969-43.697 ± 11.1836
Month 12 (n=121,109)-45.530 ± 10.5112-45.727 ± 13.5336
Month 18 (n=116,101)-47.101 ± 10.5592-44.818 ± 13.2623
Month 24 (n=111,96)-46.944 ± 11.9490-46.417 ± 13.8658
Month 30 (n=112,94)-46.631 ± 12.0206-47.734 ± 12.6696
Month 36/ET (n=123,117)-43.785 ± 13.5585-39.863 ± 17.5411
PrimaryHigh-Density Lipoprotein Cholesterol (HDL-C; mMol/L) During the Study

Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · mMol/L
High-Density Lipoprotein Cholesterol (HDL-C; mMol/L) During the Study
mMol/LAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Baseline (n=139,132)1.349 ± 0.27321.277 ± 0.2546
Month 1 (n=131,130)1.360 ± 0.27171.292 ± 0.2650
Change at Month 1 (n=131,130)0.010 ± 0.16850.016 ± 0.1740
Month 2 (n=132,122)1.364 ± 0.28051.297 ± 0.2625
Change at Month 2 (n=132,122)0.014 ± 0.22380.025 ± 0.1600
Month 3 (n=126,117)1.371 ± 0.27681.274 ± 0.2606
Change at Month 3 (n=126,117)0.015 ± 0.19430.011 ± 0.1837
Month 6 (n=127,115)1.337 ± 0.28341.268 ± 0.2311
Change at Month 6 (n=127,115)-0.011 ± 0.18480.010 ± 0.1833
Month 12 (n=121,109)1.328 ± 0.28851.241 ± 0.2429
Change at Month 12 (n=121,109)-0.012 ± 0.1945-0.023 ± 0.1727
Month 18 (n=116,102)1.367 ± 0.30031.234 ± 0.2349
Change at Month 18 (n=116,102)0.024 ± 0.1923-0.027 ± 0.1744
Month 24 (n=111,96)1.385 ± 0.27291.266 ± 0.2443
Change at Month 24 (n=111,96)0.027 ± 0.20430.007 ± 0.1910
Month 30 (n=112,94)1.380 ± 0.29421.265 ± 0.2487
Change at Month 30 (n=112,94)0.032 ± 0.19970.006 ± 0.2150
Month 36/ET (n=123,117)1.335 ± 0.29181.278 ± 0.2516
Change at Month 36/ET (n=123,117)-0.024 ± 0.19490.005 ± 0.1975
PrimaryPercent Change From Baseline in HDL-C

Assessments were performed in the fasting state (minimum 10-hour fast).

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in HDL-C
percent changeAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Month 1 (n=131,130)1.526 ± 12.78452.192 ± 14.0769
Month 2 (n=132,122)2.195 ± 15.68822.544 ± 12.7802
Month 3 (n=126,117)1.929 ± 14.73291.674 ± 14.9525
Month 6 (n=127,115)-0.016 ± 14.88531.877 ± 14.9113
Month 12 (n=121,109)-0.069 ± 15.2821-1.023 ± 14.1983
Month 18 (n=116,102)2.472 ± 14.8939-1.165 ± 14.3783
Month 24 (n=111,96)3.014 ± 14.95591.737 ± 15.6924
Month 30 (n=112,94)3.345 ± 15.50801.868 ± 17.2633
Month 36/ET (n=123,117)-1.125 ± 14.78161.602 ± 15.4895
PrimaryTotal Cholesterol (mMol/L) During the Study

Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · mMol/L
Total Cholesterol (mMol/L) During the Study
mMol/LAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Baseline (n=139,132)8.056 ± 1.33567.647 ± 1.2250
Month 1 (n=134,131)5.785 ± 1.04975.352 ± 0.9345
Change at Month 1 (n=134,131)-2.266 ± 0.7957-2.297 ± 0.8516
Month 2 (n=132,124)5.435 ± 0.86295.061 ± 0.7865
Change at Month 2 (n=132,124)-2.620 ± 0.9581-2.654 ± 0.9707
Month 3 (n=127,118)5.195 ± 0.80004.883 ± 0.7034
Change at Month 3 (n=127,118)-2.869 ± 1.0904-2.883 ± 1.1363
Month 6 (n=127,115)5.019 ± 0.63804.982 ± 0.6620
Change at Month 6 (n=127,115)-3.063 ± 1.1687-2.809 ± 1.1133
Month 12 (n=121,109)5.081 ± 0.74704.799 ± 0.7176
Change at Month 12 (n=121,109)-3.040 ± 1.1353-2.945 ± 1.2112
Month 18 (n=116,101)4.989 ± 0.65124.845 ± 0.5401
Change at Month 18 (n=116,101)-3.168 ± 1.1990-2.965 ± 1.2667
Month 24 (n=111,96)5.032 ± 0.71114.817 ± 0.7413
Change at Month 24 (n=111,96)-3.123 ± 1.2039-3.009 ± 1.2871
Month 30 (n=112,95)5.075 ± 0.69514.795 ± 0.8256
Change at Month 30 (n=112,95)-3.096 ± 1.2999-3.048 ± 1.2716
Month 36/ET (n=123,117)5.134 ± 0.78635.099 ± 0.9318
Change at Month 36/ET (n=123,117)-2.923 ± 1.3256-2.543 ± 1.3669
PrimaryPercent Change From Baseline in Total Cholesterol

Assessments were performed in the fasting state (minimum 10-hour fast).

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in Total Cholesterol
percent changeAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Month 1 (n=134,131)-27.879 ± 8.2639-29.653 ± 8.5987
Month 2 (n=132,124)-31.900 ± 8.5025-33.726 ± 9.2319
Month 3 (n=127,118)-34.784 ± 9.4141-36.126 ± 11.0136
Month 6 (n=127,115)-36.889 ± 9.2297-35.055 ± 10.0273
Month 12 (n=121,109)-36.541 ± 9.2486-36.943 ± 11.9418
Month 18 (n=116,101)-37.772 ± 9.7325-36.634 ± 11.4572
Month 24 (n=111,96)-37.287 ± 9.9578-37.317 ± 12.2461
Month 30 (n=112,95)-36.662 ± 11.2064-37.856 ± 12.5116
Month 36/ET (n=123,117)-35.063 ± 12.0345-32.013 ± 14.5000
PrimaryTrigylcerides (mMol/L) During the Study

Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · mMol/L
Trigylcerides (mMol/L) During the Study
mMol/LAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Baseline (n=139,132)0.880 ± 0.43430.980 ± 0.4986
Month 1 (n=134,131)0.759 ± 0.39580.815 ± 0.3848
Change at Month 1 (n=134,131)-0.121 ± 0.3895-0.166 ± 0.5024
Month 2 (n=132,124)0.772 ± 0.38370.741 ± 0.3382
Change at Month 2 (n=132,124)-0.103 ± 0.3652-0.246 ± 0.4825
Month 3 (n=127,118)0.699 ± 0.29160.748 ± 0.3357
Change at Month 3 (n=127,118)-0.166 ± 0.3937-0.237 ± 0.4466
Month 6 (n=127,115)0.691 ± 0.36020.801 ± 0.3848
Change at Month 6 (n=127,115)-0.183 ± 0.4305-0.188 ± 0.4880
Month 12 (n=121,109)-0.747 ± 0.39010.789 ± 0.4050
Change at Month 12 (n=121,109)-0.136 ± 0.4060-0.181 ± 0.5255
Month 18 (n=116,102)0.687 ± 0.34350.765 ± 0.3438
Change at Month 18 (n=116,102)-0.190 ± 0.3665-0.219 ± 0.4623
Month 24 (n=111,96)0.725 ± 0.36760.790 ± 0.3651
Change at Month 24 (n=111,96)-0.133 ± 0.4112-0.179 ± 0.4956
Month 30 (n=112,95)0.788 ± 0.34540.781 ± 0.4167
Change at Month 30 (n=112,95)-0.082 ± 0.3898-0.187 ± 0.5728
Month 36/ET (n=123,117)0.764 ± 0.42200.794 ± 0.3894
Change at Month 36/ET (n=123,117)-0.092 ± 0.4615-0.171 ± 0.5216
PrimaryPercent Change From Baseline in Trigylcerides

Assessments were performed in the fasting state (minimum 10-hour fast).

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in Trigylcerides
percent changeAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Month 1 (n=134,131)-5.950 ± 39.0995-5.927 ± 51.1811
Month 2 (n=132,124)-3.260 ± 42.5136-14.832 ± 40.4952
Month 3 (n=127,118)-8.760 ± 41.1184-14.415 ± 39.9951
Month 6 (n=127,115)-11.817 ± 41.9879-9.097 ± 43.0350
Month 12 (n=121,109)-7.981 ± 40.4511-7.950 ± 48.7238
Month 18 (n=116,102)-13.113 ± 39.3990-12.443 ± 37.3822
Month 24 (n=111,96)-6.697 ± 38.7027-7.328 ± 45.3694
Month 30 (n=112,95)0.657 ± 43.3886-4.935 ± 63.1887
Month 36/ET (n=123,117)-0.703 ± 50.6333-7.759 ± 45.6372
PrimaryVery Low-Density Lipoprotein (VLDL; mMol/L) During the Study

Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · mMol/L
Very Low-Density Lipoprotein (VLDL; mMol/L) During the Study
mMol/LAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Baseline (n=139,132)0.403 ± 0.19930.449 ± 0.2288
Month 1 (n=134,131)0.348 ± 0.18230.374 ± 0.1770
Change at Month 1 (n=134,131)-0.056 ± 0.1793-0.076 ± 0.2307
Month 2 (n=132,124)0.354 ± 0.17570.340 ± 0.1541
Change at Month 2 (n=132,124)-0.047 ± 0.1672-0.113 ± 0.2215
Month 3 (n=127,118)0.320 ± 0.13330.344 ± 0.1548
Change at Month 3 (n=127,118)-0.076 ± 0.1805-0.108 ± 0.2044
Month 6 (n=127,115)0.317 ± 0.16520.367 ± 0.1767
Change at Month 6 (n=127,115)-0.084 ± 0.1977-0.086 ± 0.2240
Month 12 (n=121,109)0.343 ± 0.17860.362 ± 0.1862
Change at Month 12 (n=121,109)-0.062 ± 0.1872-0.082 ± 0.2421
Month 18 (n=116,101)0.315 ± 0.15710.349 ± 0.1571
Change at Month 18 (n=116,101)-0.087 ± 0.1680-0.102 ± 0.2126
Month 24 (n=111,96)0.332 ± 0.16800.363 ± 0.1680
Change at Month 24 (n=111,96)-0.061 ± 0.1887-0.081 ± 0.2285
Month 30 (n=112,95)0.361 ± 0.15810.358 ± 0.1914
Change at Month 30 (n=112,95)-0.038 ± 0.1781-0.086 ± 0.2621
Month 36/ET (n=123,117)0.350 ± 0.19300.364 ± 0.1782
Change at Month 36/ET (n=123,117)-0.042 ± 0.2112-0.079 ± 0.2385
PrimaryPercent Change From Baseline in VLDL

Assessments were performed in the fasting state (minimum 10-hour fast).

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in VLDL
percent changeAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Month 1 (n=134,131)-6.060 ± 39.3300-5.805 ± 51.7264
Month 2 (n=132,124)-3.097 ± 42.3626-14.694 ± 40.1710
Month 3 (n=127,118)-8.711 ± 41.2631-14.263 ± 39.7239
Month 6 (n=127,115)-11.591 ± 42.4219-9.158 ± 43.1397
Month 12 (n=121,109)-7.739 ± 40.7579-7.827 ± 48.9819
Month 18 (n=116,101)-12.911 ± 39.7908-12.768 ± 37.4142
Month 24 (n=111,96)-6.654 ± 38.7945-6.920 ± 46.3317
Month 30 (n=112,95)0.627 ± 43.6239-4.751 ± 64.2502
Month 36/ET (n=123,117)-0.520 ± 51.3422-7.842 ± 45.4640
PrimaryApoliprotein A-1 (Apo A-1; Grams Per Liter [g/L]) During the Study

Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · g/L
Apoliprotein A-1 (Apo A-1; Grams Per Liter [g/L]) During the Study
g/LAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Baseline (n=138,132)1.396 ± 0.18391.308 ± 0.2006
Month 1 (n=132,130)1.419 ± 0.22331.337 ± 0.1927
Change at Month 1 (n=132,130)0.025 ± 0.16390.032 ± 0.1506
Month 2 (n=131,123)1.411 ± 0.19521.334 ± 0.1950
Change at Month 2 (n=131,123)0.016 ± 0.15190.025 ± 0.1355
Month 3 (n=126,117)1.405 ± 0.19141.306 ± 0.1919
Change at Month 3 (n=126,117)0.005 ± 0.17130.006 ± 0.1557
Month 6 (n=123,110)1.386 ± 0.20811.329 ± 0.1894
Change at Month 6 (n=123,110)-0.007 ± 0.16090.026 ± 0.1818
Month 12 (n=120,108)1.347 ± 0.18931.271 ± 0.1798
Change at Month 12 (n=120,108)-0.041 ± 0.1574-0.028 ± 0.1586
Month 18 (n=114,100)1.339 ± 0.19721.266 ± 0.1676
Change at Month 18 (n=114,100)-0.049 ± 0.1558-0.038 ± 0.1643
Month 24 (n=113,95)1.364 ± 0.19291.275 ± 0.1736
Change at Month 24 (n=113,95)-0.032 ± 0.1749-0.027 ± 0.1799
Month 30 (n=112,95)1.357 ± 0.22471.268 ± 0.1848
Change at Month 30 (n=112,95)-0.040 ± 0.1857-0.036 ± 0.1861
Month 36/ET (n=125,118)1.327 ± 0.20811.272 ± 0.1664
Change at Month 36/ET (n=125,118)-0.073 ± 0.1725-0.040 ± 0.1676
PrimaryPercent Change From Baseline in Apo A-1

Assessments were performed in the fasting state (minimum 10-hour fast).

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in Apo A-1
percent changeAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Month 1 (n=132,130)2.229 ± 12.40013.301 ± 12.2009
Month 2 (n=131,123)1.701 ± 11.03642.499 ± 10.7656
Month 3 (n=126,117)1.041 ± 12.42041.192 ± 12.1640
Month 6 (n=123,110)-0.069 ± 12.11093.011 ± 14.1347
Month 12 (n=120,108)-2.365 ± 11.5882-1.370 ± 12.3901
Month 18 (n=114,100)-3.042 ± 11.2219-1.980 ± 12.2170
Month 24 (n=113,95)-1.611 ± 12.4618-0.961 ± 13.9868
Month 30 (n=112,95)-2.342 ± 13.3357-1.695 ± 14.2732
Month 36/ET (n=125,118)-4.804 ± 12.0443-1.954 ± 12.7229
PrimaryApoliprotein B (Apo B; g/L) During the Study

Assessments were performed in the fasting state (minimum 10-hour fast). Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · g/L
Apoliprotein B (Apo B; g/L) During the Study
g/LAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Baseline (n=138,132)1.454 ± 0.28901.381 ± 0.2619
Month 1 (n=132,130)1.062 ± 0.24230.967 ± 0.2257
Change at Month 1 (n=132,130)-0.395 ± 0.1599-0.415 ± 0.1691
Month 2 (n=131,123)0.980 ± 0.19290.916 ± 0.1813
Change at Month 2 (n=131,123)-0.471 ± 0.1825-0.484 ± 0.1858
Month 3 (n=126,117)0.930 ± 0.18360.890 ± 0.1707
Change at Month 3 (n=126,117)-0.522 ± 0.2152-0.518 ± 0.2184
Month 6 (n=123,110)0.919 ± 0.15570.910 ± 0.1683
Change at Month 6 (n=123,110)-0.535 ± 0.2092-0.503 ± 0.2086
Month 12 (n=120,108)0.918 ± 0.18160.871 ± 0.1493
Change at Month 12 (n=120,108)-0.548 ± 0.2131-0.530 ± 0.2194
Month 18 (n=114,100)0.893 ± 0.15460.882 ± 0.1293
Change at Month 18 (n=114,100)-0.578 ± 0.2343-0.533 ± 0.2463
Month 24 (n=113,95)0.918 ± 0.17190.884 ± 0.1575
Change at Month 24 (n=113,95)-0.551 ± 0.2353-0.535 ± 0.2344
Month 30 (n=112,95)0.910 ± 0.17230.885 ± 0.1717
Change at Month 30 (n=112,95)-0.560 ± 0.2664-0.533 ± 0.2467
Month 36/ET (n=125,118)0.926 ± 0.18600.924 ± 0.2173
Change at Month 36/ET (n=125,118)-0.520 ± 0.2730-0.450 ± 0.2748
PrimaryPercent Change From Baseline in Apo B

Assessments were performed in the fasting state (minimum 10-hour fast).

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in Apo B
percent changeAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Month 1 (n=132,130)-26.933 ± 9.5550-29.851 ± 10.3544
Month 2 (n=131,123)-31.867 ± 9.2821-33.959 ± 9.9478
Month 3 (n=126,117)-35.163 ± 10.5680-35.849 ± 11.6832
Month 6 (n=123,110)-35.900 ± 9.3398-34.740 ± 10.7982
Month 12 (n=120,108)-36.624 ± 9.7413-36.842 ± 11.6106
Month 18 (n=114,100)-38.158 ± 10.4084-36.211 ± 12.7805
Month 24 (n=113,95)-36.426 ± 11.4333-36.677 ± 12.1824
Month 30 (n=112,95)-36.668 ± 12.8783-36.453 ± 13.6888
Month 36/ET (n=125,118)-34.507 ± 14.0740-31.362 ± 16.4770
PrimaryNumber of Participants With Shift From Baseline in Tanner_Stage by Timepoint and Baseline Tanner_Stage

Tanner_Stage was assessed based on 2 components by gender, pubic hair and breasts for females and pubic hair and genitalia for males. If these values of components were not same, then the Tanner_Stage had the higher value of 2 components for each gender by visit.

Time frame:
Baseline, Months 6, 12, 18, 24, 30, and 36/ET
Reported as:
Number · participants
Number of Participants With Shift From Baseline in Tanner_Stage by Timepoint and Baseline Tanner_Stage
participantsAtorvastatin (5-80 mg): Baseline Tanner_Stage 1Atorvastatin (10-80 mg): Baseline Tanner_Stage 2Atorvastatin (10-80 mg): Baseline Tanner_Stage 3Atorvastatin (10-80 mg): Baseline Tanner_Stage 4Atorvastatin (10-80 mg): Baseline Tanner_Stage 5
Tanner_Stage 1, Month 6 (n=126,48,25,27,15)1070000
Tanner_Stage 2 , Month 6 (n=126,48,25,27,15)1434000
Tanner_Stage 3, Month 6 (n=126,48,25,27,15)5101400
Tanner_Stage 4, Month 6 (n=126,48,25,27,15)0411251
Tanner_Stage 5, Month 6 (n=126,48,25,27,15)000214
Tanner_Stage 1, Month 12 (n=121,43,23,26,15)850000
Tanner_Stage 2, Month 12 (n=121,43,23,26,15)2517000
Tanner_Stage 3, Month 12 (n=121,43,23,26,15)10211100
Tanner_Stage 4, Month 12 (n=121,43,23,26,15)1510221
Tanner_Stage 5, Month 12 (n=121,43,23,26,15)002414
Tanner_Stage 1, Month 18 (n=115,41, 21,25,14)630000
Tanner_Stage 2, Month 18 (n=115,41, 21,25,14)3115000
Tanner_Stage 3, Month 18 (n=115,41, 21,25,14)1816600
Tanner_Stage 4, Month 18 (n=115,41, 21,25,14)3911181
Tanner_Stage 5, Month 18 (n=115,41, 21,25,14)014713
Tanner_Stage 1, Month 24 (n=113,38,19,22,14)510000
Tanner_Stage 2, Month 24 (n=113,38,19,22,14)339000
Tanner_Stage 3, Month 24 (n=113,38,19,22,14)2014200
Tanner_Stage 4, Month 24 (n=113,38,19,22,14)91213131
Tanner_Stage 5, Month 24 (n=113,38,19,22,14)034913
Tanner_Stage 1, Month 30 (n=111,38,19,23,14)390000
Tanner_Stage 2, Month 30 (n=111,38,19,23,14)323000
Tanner_Stage 3, Month 30 (n=111,38,19,23,14)2611100
Tanner_Stage 4, Month 30 (n=111,38,19,23,14)14189111
Tanner_Stage 5, Month 30 (n=111,38,19,23,14)0691213
Tanner_Stage 1, Month 36/ET (n=127,52,25,31,18)410000
Tanner_Stage 2, Month 36/ET (n=127,52,25,31,18)316000
Tanner_Stage 3, Month 36/ET (n=127,52,25,31,18)2510200
Tanner_Stage 4, Month 36/ET (n=127,52,25,31,18)252413120
Tanner_Stage 5, Month 36/ET (n=127,52,25,31,18)512101918
PrimaryHeight (Centimeters [cm]) During the Study: Males

Investigator assessment of height changes during the study. Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · cm
Height (Centimeters [cm]) During the Study: Males
cmAtorvastatin (5-80 mg)
Baseline (n=146)144.36 ± 16.004
Month 1 (n=141)145.21 ± 16.114
Change at Month 1 (n=141)0.68 ± 0.964
Month 2 (n=138)145.93 ± 16.302
Change at Month 2 (n=138)1.27 ± 0.964
Month 3 (n=133)146.00 ± 16.139
Change at Month 3 (n=133)1.72 ± 1.172
Month 6 (n=129)147.17 ± 16.033
Change at Month 6 (n=129)3.24 ± 1.485
Month 12 (n=123)150.75 ± 16.321
Change at Month 12 (n=123)6.67 ± 2.385
Month 18 (n=119)153.26 ± 16.388
Change at Month 18 (n=119)9.31 ± 2.978
Month 24 (n=114)156.03 ± 16.001
Change at Month 24 (n=114)12.11 ± 3.630
Month 30 (n=114)158.78 ± 15.770
Change at Month 30 (n=114)14.86 ± 4.403
Month 36/ET (n=134)160.59 ± 15.602
Change at Month 36/ET (n=134)15.53 ± 6.801
PrimaryPercent Change From Baseline in Height: Males

Investigator assessment of height changes during the study.

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in Height: Males
percent changeAtorvastatin (5-80 mg)
Month 1 (n=141)0.47 ± 0.689
Month 2 (n=138)0.88 ± 0.652
Month 3 (n=133)1.19 ± 0.777
Month 6 (n=129)2.25 ± 0.987
Month 12 (n=123)4.66 ± 1.606
Month 18 (n=119)6.53 ± 2.021
Month 24 (n=114)8.53 ± 2.607
Month 30 (n=114)10.49 ± 3.260
Month 36/ET (n=134)10.97 ± 5.010
PrimaryHeight (cm) During the Study: Females

Investigator assessment of height changes during the study. Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · cm
Height (cm) During the Study: Females
cmAtorvastatin (5-80 mg)
Baseline (n=125)145.28 ± 14.108
Month 1 (n=124)146.06 ± 14.045
Change at Month 1 (n=124)0.71 ± 1.378
Month 2 (n=119)146.57 ± 13.919
Change at Month 2 (n=119)1.19 ± 1.700
Month 3 (n=115)146.81 ± 13.838
Change at Month 3 (n=115)1.68 ± 1.278
Month 6 (n=113)147.87 ± 13.619
Change at Month 6 (n=113)2.77 ± 1.720
Month 12 (n=107)150.84 ± 12.968
Change at Month 12 (n=107)5.50 ± 2.992
Month 18 (n=99)152.77 ± 12.648
Change at Month 18 (n=99)7.41 ± 4.043
Month 24 (n=95)154.79 ± 11.913
Change at Month 24 (n=95)9.61 ± 5.120
Month 30 (n=93)156.43 ± 11.288
Change at Month 30 (n=93)11.23 ± 6.118
Month 36/ET (n=121)156.52 ± 11.032
Change at Month 36/ET (n=121)11.23 ± 7.551
PrimaryPercent Change From Baseline in Height: Females

Investigator assessment of height changes during the study.

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in Height: Females
percent changeAtorvastatin (5-80 mg)
Month 1 (n=124)0.51 ± 1.004
Month 2 (n=119)0.84 ± 1.220
Month 3 (n=115)1.20 ± 0.925
Month 6 (n=113)1.98 ± 1.291
Month 12 (n=107)3.93 ± 2.262
Month 18 (n=99)5.30 ± 3.036
Month 24 (n=95)6.93 ± 3.933
Month 30 (n=93)8.13 ± 4.740
Month 36/ET (n=121)8.14 ± 5.789
PrimaryWeight (Kilograms [kg]) During the Study: Males

Investigator assessment of weight changes during the study. Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · kg
Weight (Kilograms [kg]) During the Study: Males
kgAtorvastatin (5-80 mg)
Baseline (n=146)40.79 ± 14.079
Month 1 (n=141)41.18 ± 14.287
Change at Month 1 (n=141)0.36 ± 1.203
Month 2 (n=138)41.83 ± 14.467
Change at Month 2 (n=138)0.80 ± 1.422
Month 3 (n=133)41.68 ± 14.266
Change at Month 3 (n=133)1.08 ± 1.907
Month 6 (n=129)42.47 ± 14.564
Change at Month 6 (n=129)2.00 ± 2.528
Month 12 (n=123)45.29 ± 15.526
Change at Month 12 (n=123)4.65 ± 3.822
Month 18 (n=119)47.53 ± 16.164
Change at Month 18 (n=119)7.02 ± 4.432
Month 24 (n=114)49.77 ± 16.401
Change at Month 24 (n=114)9.27 ± 5.079
Month 30 (n=114)52.12 ± 17.100
Change at Month 30 (n=114)11.61 ± 6.032
Month 36/ET (n=134)53.50 ± 16.787
Change at Month 36/ET (n=134)12.35 ± 6.771
PrimaryPercent Change From Baseline in Weight: Males

Investigator assessment of weight changes during the study.

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in Weight: Males
percent changeAtorvastatin (5-80 mg)
Month 1 (n=141)0.94 ± 2.739
Month 2 (n=138)2.04 ± 3.262
Month 3 (n=133)2.73 ± 4.317
Month 6 (n=129)5.09 ± 5.559
Month 12 (n=123)11.85 ± 8.172
Month 18 (n=119)18.03 ± 9.629
Month 24 (n=114)24.28 ± 11.696
Month 30 (n=114)30.46 ± 14.058
Month 36/ET (n=134)32.54 ± 17.409
PrimaryWeight (kg) During the Study: Females

Investigator assessment of weight changes during the study. Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · kg
Weight (kg) During the Study: Females
kgAtorvastatin (5-80 mg)
Baseline (n=125)42.14 ± 14.038
Month 1 (n=125)42.50 ± 14.007
Change at Month 1 (n=125)0.36 ± 0.924
Month 2 (n=120)42.86 ± 14.209
Change at Month 2 (n=120)0.67 ± 1.338
Month 3 (n=115)43.34 ± 14.753
Change at Month 3 (n=115)1.24 ± 1.819
Month 6 (n=113)44.26 ± 15.027
Change at Month 6 (n=113)2.10 ± 2.409
Month 12 (n=107)46.61 ± 15.158
Change at Month 12 (n=107)4.41 ± 3.317
Month 18 (n=99)48.32 ± 14.670
Change at Month 18 (n=99)6.24 ± 4.291
Month 24 (n=95)50.13 ± 14.731
Change at Month 24 (n=95)8.55 ± 5.038
Month 30 (n=93)51.73 ± 14.681
Change at Month 30 (n=93)10.02 ± 6.127
Month 36/ET (n=121)51.55 ± 14.498
Change at Month 36/ET (n=121)9.77 ± 7.047
PrimaryPercent Change From Baseline in Weight: Females

Investigator assessment of weight changes during the study.

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in Weight: Females
percent changeAtorvastatin (5-80 mg)
Month 1 (n=125)0.97 ± 2.303
Month 2 (n=120)1.85 ± 3.206
Month 3 (n=115)3.16 ± 4.149
Month 6 (n=113)5.37 ± 5.529
Month 12 (n=107)11.65 ± 8.391
Month 18 (n=99)16.79 ± 11.315
Month 24 (n=95)23.43 ± 14.333
Month 30 (n=93)27.83 ± 17.507
Month 36/ET (n=121)27.26 ± 21.389
PrimaryBody Mass Index (BMI in kg Per Square Meter [kg/m^2]) During the Study: Males

Investigator assessment of BMI changes during the study. Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · kg/m^2
Body Mass Index (BMI in kg Per Square Meter [kg/m^2]) During the Study: Males
kg/m^2Atorvastatin (5-80 mg)
Baseline (n=146)18.97 ± 3.664
Month 1 (n=141)18.94 ± 3.751
Change at Month 1 (n=141)0.01 ± 0.577
Month 2 (n=138)19.06 ± 3.755
Change at Month 2 (n=138)0.06 ± 0.658
Month 3 (n=133)18.99 ± 3.745
Change at Month 3 (n=133)0.07 ± 0.890
Month 6 (n=129)19.04 ± 3.881
Change at Month 6 (n=129)0.10 ± 1.218
Month 12 (n=123)19.34 ± 3.922
Change at Month 12 (n=123)0.37 ± 1.541
Month 18 (n=119)19.65 ± 4.053
Change at Month 18 (n=119)0.73 ± 1.625
Month 24 (n=114)19.91 ± 4.098
Change at Month 24 (n=114)0.99 ± 1.745
Month 30 (n=114)20.18 ± 4.400
Change at Month 30 (n=114)1.25 ± 2.099
Month 36/ET (n=134)20.28 ± 4.137
Change at Month 36/ET (n=134)1.33 ± 1.958
PrimaryPercent Change From Baseline in BMI: Males

Investigator assessment of BMI changes during the study.

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in BMI: Males
percent changeAtorvastatin (5-80 mg)
Month 1 (n=141)0.03 ± 2.953
Month 2 (n=138)0.31 ± 3.405
Month 3 (n=133)0.39 ± 4.496
Month 6 (n=129)0.55 ± 5.673
Month 12 (n=123)2.10 ± 7.065
Month 18 (n=119)3.98 ± 7.533
Month 24 (n=114)5.45 ± 8.306
Month 30 (n=114)6.80 ± 9.737
Month 36/ET (n=134)7.31 ± 9.290
PrimaryBMI (kg/m^2) During the Study: Females

Investigator assessment of BMI changes during the study. Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · kg/m^2
BMI (kg/m^2) During the Study: Females
kg/m^2Atorvastatin (5-80 mg)
Baseline (n=125)19.44 ± 3.994
Month 1 (n=124)19.45 ± 3.973
Change at Month 1 (n=124)-0.02 ± 0.582
Month 2 (n=119)19.47 ± 3.940
Change at Month 2 (n=119)0.00 ± 0.756
Month 3 (n=115)19.54 ± 4.171
Change at Month 3 (n=115)0.13 ± 0.861
Month 6 (n=113)19.68 ± 4.288
Change at Month 6 (n=113)0.24 ± 1.004
Month 12 (n=107)19.98 ± 4.257
Change at Month 12 (n=107)0.60 ± 1.305
Month 18 (n=99)20.24 ± 3.990
Change at Month 18 (n=99)0.92 ± 1.432
Month 24 (n=95)20.50 ± 3.976
Change at Month 24 (n=95)1.38 ± 1.624
Month 30 (n=93)20.75 ± 4.014
Change at Month 30 (n=93)1.59 ± 1.931
Month 36/ET (n=121)20.71 ± 4.217
Change at Month 36/ET (n=121)1.46 ± 1.948
PrimaryPercent Change From Baseline in BMI: Females

Investigator assessment of BMI changes during the study.

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in BMI: Females
percent changeAtorvastatin (5-80 mg)
Month 1 (n=124)-0.06 ± 3.058
Month 2 (n=119)0.16 ± 3.777
Month 3 (n=115)0.73 ± 4.314
Month 6 (n=113)1.26 ± 4.992
Month 12 (n=107)3.33 ± 6.765
Month 18 (n=99)5.14 ± 7.578
Month 24 (n=95)7.68 ± 8.661
Month 30 (n=93)8.89 ± 9.916
Month 36/ET (n=121)8.06 ± 10.147
PrimaryAge (Years) During the Study: Males

Investigator assessment of age during the study. Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · years
Age (Years) During the Study: Males
yearsAtorvastatin (5-80 mg)
Baseline (n=146)9.94 ± 2.489
Month 1 (n=141)10.05 ± 2.553
Change at Month 1 (n=141)0.11 ± 0.309
Month 2 (n=138)10.14 ± 2.583
Change at Month 2 (n=138)0.18 ± 0.387
Month 3 (n=133)10.21 ± 2.567
Change at Month 3 (n=133)0.29 ± 0.457
Month 6 (n=129)10.43 ± 2.552
Change at Month 6 (n=129)0.55 ± 0.499
Month 12 (n=123)10.96 ± 2.543
Change at Month 12 (n=123)1.02 ± 0.155
Month 18 (n=119)11.47 ± 2.544
Change at Month 18 (n=119)1.54 ± 0.501
Month 24 (n=114)11.93 ± 2.534
Change at Month 24 (n=114)2.02 ± 0.132
Month 30 (n=114)12.46 ± 2.553
Change at Month 30 (n=114)2.54 ± 0.500
Month 36/ET (n=134)12.69 ± 2.587
Change at Month 36/ET (n=134)2.67 ± 0.899
PrimaryPercent Change From Baseline in Age: Males

Investigator assessment of age during the study.

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in Age: Males
percent changeAtorvastatin (5-80 mg)
Month 1 (n=141)1.09 ± 3.327
Month 2 (n=138)1.86 ± 4.184
Month 3 (n=133)3.16 ± 5.175
Month 6 (n=129)6.06 ± 5.956
Month 12 (n=123)11.13 ± 3.878
Month 18 (n=119)16.82 ± 7.732
Month 24 (n=114)21.92 ± 6.623
Month 30 (n=114)27.67 ± 9.855
Month 36/ET (n=134)28.90 ± 13.486
PrimaryAge (Years) During the Study: Females

Investigator assessment of age during the study. Change from baseline was also determined.

Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · years
Age (Years) During the Study: Females
yearsAtorvastatin (5-80 mg)
Baseline (n=125)10.55 ± 2.421
Month 1 (n=125)10.66 ± 2.436
Change at Month 1 (n=125)0.11 ± 0.317
Month 2 (n=120)10.78 ± 2.430
Change at Month 2 (n=120)0.20 ± 0.402
Month 3 (n=115)10.75 ± 2.449
Change at Month 3 (n=115)0.28 ± 0.450
Month 6 (n=113)10.99 ± 2.477
Change at Month 6 (n=113)0.52 ± 0.502
Month 12 (n=107)11.50 ± 2.416
Change at Month 12 (n=107)0.99 ± 0.097
Month 18 (n=99)12.02 ± 2.503
Change at Month 18 (n=99)1.52 ± 0.502
Month 24 (n=95)12.42 ± 2.482
Change at Month 24 (n=95)1.98 ± 0.144
Month 30 (n=93)12.99 ± 2.564
Change at Month 30 (n=93)2.52 ± 0.502
Month 36/ET (n=121)13.07 ± 2.547
Change at Month 36/ET (n=121)2.54 ± 0.940
PrimaryPercent Change From Baseline in Age: Females

Investigator assessment of age during the study.

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in Age: Females
percent changeAtorvastatin (5-80 mg)
Month 1 (n=125)1.10 ± 3.169
Month 2 (n=120)2.00 ± 4.128
Month 3 (n=115)2.74 ± 4.549
Month 6 (n=113)5.18 ± 5.221
Month 12 (n=107)10.00 ± 2.811
Month 18 (n=99)15.20 ± 6.006
Month 24 (n=95)20.08 ± 5.298
Month 30 (n=93)25.35 ± 7.415
Month 36/ET (n=121)25.73 ± 12.168
SecondaryPercentage of Participants With Overall Expected Maturation and Development Consistent With Expectations as Assessed by the Investigator
Time frame:
Baseline, Months 1, 2, 3, 6, 12, 18, 24, 30 and 36 (or early termination)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Expected Maturation and Development Consistent With Expectations as Assessed by the Investigator
percentage of participantsAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Baseline (n=139,132)99.3100.0
Month 1 (n=118,113)100.0100.0
Month 2 (n=116,109)100.0100.0
Month 3 (n=130,118)100.0100.0
Month 6 (n=127,115)100.099.1
Month 12 (n=121,109)100.099.1
Month 18 (n=115,102)100.0100.0
Month 24 (n=113,95)100.0100.0
Month 30 (n=111,94)100.098.9
Month 36/Early Termination (n=128,127)99.299.2
PrimaryFlow-Mediated Dilatation (FMD) During the Study

Percent (%) FMD was calculated as (hyperemic diameter minus resting diameter) divided by the resting diameter multiplied by 100. Change from baseline was also determined.

Time frame:
Baseline, Months 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · % FMD
Flow-Mediated Dilatation (FMD) During the Study
% FMDAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Baseline (n=37,36)5.523 ± 3.20626.651 ± 4.4926
Month 6 (n=27,23)5.749 ± 2.50476.520 ± 4.0763
Change at Month 6 (n=27,23)-0.063 ± 3.4768-0.759 ± 4.8732
Month 12 (n=32,29)4.732 ± 1.84776.363 ± 8.0370
Change at Month 12 (n=32,29)-0.952 ± 3.6796-0.778 ± 9.4743
Month 18 (n=33,28)4.942 ± 2.67404.668 ± 3.8874
Change at Month 18 (n=33,28)-0.762 ± 3.7374-2.556 ± 6.3123
Month 24 (n=33,28)4.538 ± 2.42395.679 ± 4.3224
Change at Month 24 (n=33,28)-1.166 ± 3.2524-1.545 ± 7.2325
Month 30 (n=33,28)5.571 ± 2.71985.191 ± 2.5120
Change at Month 30 (n=33,28)-0.134 ± 3.3399-2.033 ± 5.8591
Month 36/ET (n=34,33)4.987 ± 2.25405.360 ± 2.9873
Change at Month 36/ET (n=34,33)-0.550 ± 3.6625-1.563 ± 4.8355
PrimaryPercent Change From Baseline in FMD

Percent (%) FMD was calculated as (hyperemic diameter minus resting diameter) divided by the resting diameter multiplied by 100.

Time frame:
Months 6, 12, 18, 24, 30 and 36/ET
Reported as:
Mean · percent change
Percent Change From Baseline in FMD
percent changeAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Month 6 (n=27,23)14.867 ± 67.6028-0.205 ± 60.7192
Month 12 (n=32,29)-3.880 ± 56.191015.444 ± 207.6932
Month 18 (n=33,28)-4.598 ± 68.0267-24.387 ± 81.5683
Month 24 (n=33,28)-9.992 ± 57.38683.850 ± 102.2001
Month 30 (n=33,28)7.000 ± 63.0894-18.804 ± 42.2259
Month 36/ET (n=34,33)0.648 ± 62.5814-7.506 ± 61.2361
SecondaryPercentage of Participants by Study Drug Compliance Category

Compliance to study drug was categorized as \<80%, 80% - 120%, and greater than (\>) 120%.

Time frame:
Months 1, 2, 3, 6, 12, 18, 24, 30, and 36 (or early termination)
Reported as:
Number · percentage of participants
Percentage of Participants by Study Drug Compliance Category
percentage of participantsAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
Month 1, <80% (n=135,132)3.06.8
Month 1, 80%-120% (n=135,132)97.093.2
Month 1, >120% (n=135,132)00
Month 2, <80% (n=132,126)6.87.9
Month 2, 80%-120% (n=132,126)92.492.1
Month 2, >120% (n=132,126)0.80
Month 3, <80% (n=130,118)3.87.6
Month 3, 80%-120% (n=130,118)95.492.4
Month 3, >120% (n=130,118)0.80
Month 6, <80% (n=127,115)7.99.6
Month 6, 80%-120% (n=127,115)92.190.4
Month 6, >120% (n=127,115)00
Month 12, <80% (n=121,109)7.47.3
Month 12, 80%-120% (n=121,109)92.692.7
Month 12, >120% (n=121,109)00
Month 18, <80% (n=116,102)4.35.9
Month 18, 80%-120% (n=116,102)94.094.1
Month 18, >120% (n=116,102)1.70
Month 24, <80% (n=113,95)8.89.5
Month 24, 80%-120% (n=113,95)91.289.5
Month 24, >120% (n=113,95)01.1
Month 30, <80% (n=112,94)8.06.4
Month 30, 80%-120% (n=112,94)92.092.6
Month 30, >120% (n=112,94)01.1
Month 36/ET, <80% (n=129,129)11.616.3
Month 36/ET, 80%-120% (n=129,129)86.883.7
Month 36/ET, >120% (n=129,129)1.60

Adverse events

Collected over Baseline up through Month 36. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atorvastatin (5-80 mg): Tanner_Stage 1—14/139 (10.1%)93/139 (66.9%)
Atorvastatin (10-80 mg): Tanner_Stage 2+—7/132 (5.3%)86/132 (65.2%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
AppendicitisInfections and infestations2/1390/132
Abdominal painGastrointestinal disorders1/1391/132
VomitingGastrointestinal disorders0/1391/132
Limb injuryInjury, poisoning and procedural complications0/1391/132
Lumbar vertebral fractureInjury, poisoning and procedural complications0/1391/132
Thoracic vertebral fractureInjury, poisoning and procedural complications0/1391/132
ObesityMetabolism and nutrition disorders0/1391/132
Type I diabetes mellitusMetabolism and nutrition disorders0/1391/132
SyncopeNervous system disorders1/1391/132
Suicide attemptPsychiatric disorders0/1391/132
Most frequent other events
Showing 10 of 23
Most frequent other events
EventAtorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+
NasopharyngitisInfections and infestations26/13926/132
HeadacheNervous system disorders25/13925/132
Abdominal painGastrointestinal disorders21/13910/132
Upper respiratory tract infectionInfections and infestations20/13910/132
GastroenteritisInfections and infestations17/13912/132
VomitingGastrointestinal disorders15/1397/132
PyrexiaGeneral disorders15/13913/132
InfluenzaInfections and infestations13/13914/132
Pain in extremityMusculoskeletal and connective tissue disorders14/1395/132
CoughRespiratory, thoracic and mediastinal disorders14/13911/132

Baseline characteristics

Full Analysis Set (FAS): all participants who took at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Atorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+Total
Mean8.5 ± 1.8612.0 ± 1.6810.2 ± 2.48
Sex: Female, Male
Sex: Female, Male(Participants)Atorvastatin (5-80 mg): Tanner_Stage 1Atorvastatin (10-80 mg): Tanner_Stage 2+Total
Female4679125
Male9353146
08

Study locations

40 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • University of Florida
    Gainesville, Florida 32608, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Johns Hopkins
    Baltimore, Maryland 21287, United States
  • MEDPACE Clinical Pharmacology Unit
    Cincinnati, Ohio 45212, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Cliniques Universitaires Saint-Luc / Pediatrie generale
    Bruxelles, 1200, Belgium
  • Universitaire Ziekenhuizen Leuven / Center for Metabolic Diseases
    Leuven, 3000, Belgium
  • Clinique des maladies lipidiques de Quebec Inc
    Sainte-Foy,, Quebec G1V 4M6, Canada
  • Clinique des Maladies Lipidiques de Quebec
    Quebec, G1V 4M6, Canada
  • Charite Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Augenaerztliche Gemeinschaftspraxis
    Freiburg, 79098, Germany
  • 1st Pediatrics Clinic , University of Athens, Agia Sofia Hospital
    Athens, 115 27, Greece
  • Semmelweis Medical University
    Budapest, H-1094, Hungary
  • Fejer Megyei Szent Gyorgy Korhaz
    Szekesfehervar, 8003, Hungary
  • Dipartimento di Medicina Clinica e delle Patologie Emergenti-University Hospital of Palermo
    Palermo, 90127, Italy
  • Dipartimento di Clinica e Terapia Medica, Università degli Studi di Roma La Sapienza
    Roma, 00161, Italy
  • Rikshospitalet Lipidklinikken
    Oslo, 0027, Norway
  • Poradnia Chorob Metabolicznych
    Bydgoszcz, 85-667, Poland
  • Klinika Chorob Metabolicznych
    Warszawa, 04-730, Poland
  • Hospital de la Concepcion
    San German, 683, Puerto Rico
  • Moscow State Healthcare Institution 'Morozovskaya Children's City Clinical Hospital'
    Moscow, 119049, Russian Federation
  • Saint-Petersburg State Pediatric Medical Academy
    Saint-Petersburg, 194100, Russian Federation
  • Saint-Petersburg State Healthcare Institution "Children's Polyclinic #35"
    Saint-Petersburg, 196084, Russian Federation
  • Autonomous Non-Profit Organization Medical Center 21 Century
    St Petersburg, 194044, Russian Federation
  • Metabolicka ambulancia, 2. Detská klinika Lekárskej fakulty Univerzity Komenského
    Bratislava, 833 40, Slovakia
  • Detska fakultna nemocnica Kosice-old
    Kosice, 040 01, Slovakia
  • Detska fakultna nemocnica Kosice
    Kosice, 040 11, Slovakia
  • Lipmet, s.r.o.
    Poprad, 05801, Slovakia
  • Fakultna nemocnica Trencin
    Trencin, 911 71, Slovakia
  • Hospital General Universitario de Elche
    Elche, Alicante 03202, Spain
  • Hospital de Merida
    Merida, Badajoz 6800, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Santa Creu I Sant Pau
    Barcelona, 08041, Spain
  • Hospital Sant Joan de Deu
    Esplugues de Llobregat, 08950, Spain
  • Dr. med. Jean-Marc Nuoffer
    Ch-3010 Bern, Switzerland
  • Hacettepe University Medical Faculty. Department of Pediatrics. Nutrition and Metabolism Unit
    Ankara, 06100, Turkey
  • Gazi University, Medical Faculty
    Ankara, 6500, Turkey
  • Ege University Medical Faculty
    Izmir, 35100, Turkey
09

References and documents

Publications

  • Langslet G, Breazna A, Drogari E. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2016 Sep-Oct;10(5):1153-1162.e3. doi: 10.1016/j.jacl.2016.05.010. Epub 2016 Jun 7. PubMed 27678432 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2009
First posted
Jan 23, 2009
Start
Mar 2009
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Jun 2, 2015
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00827606
Responsible party
Sponsor
First posted
Jan 23, 2009
Start date
Mar 2009
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Jun 2, 2015
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion